Staurosporinone

Staurosporinone

SCHEMBL5440281

O=C1NCc2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K11 Q16584 7/20 1.00
MAP3K9 P80192 6/20 1.00
PRKCA P17252 4/20 1.00
PRKCQ Q04759 3/20 1.00
PRKCD Q05655 3/20 1.00
GLI1 P08151 2/20 1.00
GLI2 P10070 2/20 1.00
PRKD3 O94806 2/20 1.00
PRKCG P05129 2/20 1.00
PRKCB P05771 2/20 1.00
PRKCH P24723 2/20 1.00
PRKCI P41743 2/20 1.00
PRKCE Q02156 2/20 1.00
PRKCZ Q05513 2/20 1.00
PRKD1 Q15139 2/20 1.00
CDK4 P11802 1/20 1.00
CTRB1 P17538 1/20 1.00
PRKACA P17612 1/20 1.00
PRKACG P22612 1/20 1.00
PRKACB P22694 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Staurosporinone SCHEMBL29389399 1.00 MAP3K11 (1.00) MAP3K11MAP3K9PRKCAPRKCQPRKCD
Staurosporinone SCHEMBL29374983 1.00 MAP3K11 (1.00) MAP3K11MAP3K9PRKCAPRKCQPRKCD
SCHEMBL9270827 0.88 MAP3K11 (0.78) MAP3K11MAP3K9PRKCAPRKCQPRKCD
SCHEMBL9263371 0.88 MAP3K11 (0.78) MAP3K11MAP3K9PRKCAPRKCQPRKCD
SCHEMBL9260091 0.85 ROCK2 (0.78) MAP3K11MAP3K9PRKCAPRKCQPRKCD
SCHEMBL9263506 0.85 ROCK2 (0.78) MAP3K11MAP3K9PRKCAPRKCQPRKCD
SCHEMBL13639845 0.83 MAP3K11 (1.00) MAP3K11MAP3K9PRKCAPRKCQPRKCD
SCHEMBL13140090 0.83 MAP3K11 (1.00) MAP3K11MAP3K9PRKCAPRKCQPRKCD
SCHEMBL13639843 0.83 MAP3K11 (1.00) MAP3K11MAP3K9PRKCAPRKCQPRKCD
SCHEMBL13431719 0.82 MAP3K11 (0.69) MAP3K11MAP3K9PRKCAPRKCQPRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12459893-B2 Indole-ynone mediated benzoannulation process for the preparation of carbazoles, carbazomycin A, calothrixin B and staurosporinone COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2025-11-04 US disclosed
US-20230285556-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER OMEROS CORPORATION 2023-09-14 US disclosed
EP-2914621-B1 NOVEL NTRK1 FUSION MOLECULES AND USES THEREOF FOUND MEDICINE INC (US) 2023-06-07 EP disclosed
US-20230094365-A1 PIM KINASE INHIBITOR COMPOSITIONS, METHODS, AND USES THEREOF SNAP BIO, INC. 2023-03-30 US disclosed
WO-2023039578-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER OMEROS CORPORATION (US) 2023-03-16 WO disclosed
US-20220169609-A1 INDOLE-YNONE MEDIATED BENZOANNULATION PROCESS FOR THE PREPARATION OF CARBAZOLES, CARBAZOMYCIN A, CALOTHRIXIN B AND STAUROSPORINONE COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2022-06-02 US disclosed
US-20220169609-A1 INDOLE-YNONE MEDIATED BENZOANNULATION PROCESS FOR THE PREPARATION OF CARBAZOLES, CARBAZOMYCIN A, CALOTHRIXIN B AND STAUROSPORINONE COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2022-06-02 US disclosed
US-11319320-B2 PIM kinase inhibitor compositions, methods, and uses thereof SNAP BIO, INC. (US) 2022-05-03 US disclosed
US-11319320-B2 PIM kinase inhibitor compositions, methods, and uses thereof SNAP BIO, INC. (US) 2022-05-03 US disclosed
EP-3947333-A1 INDOLE-YNONE MEDIATED BENZOANNULATION PROCESS FOR THE PREPARATION OF CARBAZOLES- CARBAZOMYCIN A, CALOTHRIXIN B AND STAUROSPORINONE Council of Scientific & Industrial Research (IN) 2022-02-09 EP disclosed
US-20070249590-A1 Substituted indolo[2,3-a]pyrrolo[3,4-c]carbazole compounds useful in treating kinase disorders JANSSEN PHARMACEUTICA N.V. (BE) 2007-10-25 US disclosed
US-20070249590-A1 Substituted indolo[2,3-a]pyrrolo[3,4-c]carbazole compounds useful in treating kinase disorders JANSSEN PHARMACEUTICA N.V. (BE) 2007-10-25 US disclosed
US-20070249590-A1 Substituted indolo[2,3-a]pyrrolo[3,4-c]carbazole compounds useful in treating kinase disorders JANSSEN PHARMACEUTICA N.V. (BE) 2007-10-25 US disclosed
EP-0434057-B1 Indolocarbazole derivatives, processes for their preparation and their use GOEDECKE AG (DE) 1996-07-31 EP disclosed
US-5489608-A FOR TREATMENT OF HEART AND BLOOD VESSEL DISEASES GOEDECKE AKTIENGESELLSCHAFT (DE) 1996-02-06 US disclosed
US-5438050-A Indolocarbazole derivatives, processes for their preparation and compositions containing them GODECKE AKTIENGESELLSCHAFT (DE) 1995-08-01 US disclosed
EP-0328000-B1 Indolocarbazole derivatives, process for their preparation and medicines containing same GOEDECKE AG (DE) 1995-01-18 EP disclosed
WO-1993024490-A1 USE OF INDOLOCARBAZOLS IN AIDS TREATMENT Gödecke Aktiengesellschaft (DE) 1993-12-09 WO disclosed
EP-0434057-A2 Indolocarbazole derivatives, processes for their preparation and their use GÖDECKE AKTIENGESELLSCHAFT (DE) 1991-06-26 EP disclosed
EP-0328000-A2 Indolocarbazole derivatives, process for their preparation and medicines containing same GÖDECKE AKTIENGESELLSCHAFT (DE) 1989-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230094365-A1 PIM KINASE INHIBITOR COMPOSITIONS, METHODS, AND USES THEREOF PIM1, PIM3, PIM2 MAP3K11 38/4885MAP3K9 22/4885PRKCA 11/4885
US-12459893-B2 Indole-ynone mediated benzoannulation process for the preparation of carbazoles, carbazomycin A, calothrixin B and staurosporinone CYC1, CYCS, CANX MAP3K11 2101/4885MAP3K9 2007/4885PRKCA 1509/4885
US-20230285556-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER TP53, CD4, MCL1 MAP3K11 3749/4885MAP3K9 4080/4885PRKCA 1356/4885
US-20070249590-A1 Substituted indolo[2,3-a]pyrrolo[3,4-c]carbazole compounds useful in treating kinase disorders PRKACA, PRKDC, PACSIN2 MAP3K11 27/4885MAP3K9 21/4885PRKCA 29/4885
US-20220169609-A1 INDOLE-YNONE MEDIATED BENZOANNULATION PROCESS FOR THE PREPARATION OF CARBAZOLES, CARBAZOMYCIN A, CALOTHRIXIN B AND STAUROSPORINONE CYC1, CYCS, CANX MAP3K11 2101/4885MAP3K9 2007/4885PRKCA 1509/4885
US-11319320-B2 PIM kinase inhibitor compositions, methods, and uses thereof PIM1, PIM2, PIM3 MAP3K11 30/4885MAP3K9 20/4885PRKCA 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.